<DOC>
	<DOCNO>NCT00002321</DOCNO>
	<brief_summary>To determine MTD dose-limiting toxicity regimen therapeutic ganciclovir , antiretroviral therapy , recombinant interleukin-2 ( aldesleukin ; Proleukin ) immune adjuvant HIV-seropositive patient . To investigate effect increase dos Proleukin time progression CMV retinitis patient treat therapeutic ganciclovir antiretroviral therapy . To evaluate incidence level anti-IL-2 antibody formation subcutaneously administer Proleukin patient population .</brief_summary>
	<brief_title>A Phase I Study Safety Proleukin ( Aldesleukin ) Combination With Ganciclovir Antiretroviral Therapy HIV Seropositive Patients With Cytomegalovirus ( CMV ) Retinitis</brief_title>
	<detailed_description>Patients receive subcutaneous Proleukin combination ganciclovir antiretroviral therapy , MTD determine .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Retinitis</mesh_term>
	<mesh_term>Cytomegalovirus Retinitis</mesh_term>
	<mesh_term>HIV Seropositivity</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<mesh_term>Ganciclovir</mesh_term>
	<mesh_term>Ganciclovir triphosphate</mesh_term>
	<criteria>Inclusion Criteria Patients must : Documented HIV seropositivity . Prior Medication : Required : FDAapproved antiretroviral therapy least 2 month prior study entry . Allowed : Prior GCSF .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 1994</verification_date>
	<keyword>Retinitis</keyword>
	<keyword>Interleukin-2</keyword>
	<keyword>Ganciclovir</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Antiviral Agents</keyword>
</DOC>